rs796943858
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000100.4(CSTB):c.218_219del(p.Leu73ProfsTer3) variant causes a frameshift change. The variant allele was found at a frequency of 0.000224 in 1,614,088 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. L73L) has been classified as Likely benign.
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00024 ( 0 hom. )
Consequence
CSTB
NM_000100.4 frameshift
NM_000100.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.03
Genes affected
CSTB (HGNC:2482): (cystatin B) The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and kininogens. This gene encodes a stefin that functions as an intracellular thiol protease inhibitor. The protein is able to form a dimer stabilized by noncovalent forces, inhibiting papain and cathepsins l, h and b. The protein is thought to play a role in protecting against the proteases leaking from lysosomes. Evidence indicates that mutations in this gene are responsible for the primary defects in patients with progressive myoclonic epilepsy (EPM1). One type of mutation responsible for EPM1 is the expansion in the promoter region of this gene of a CCCCGCCCCGCG repeat from 2-3 copies to 30-78 copies. [provided by RefSeq, Jul 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
?
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.266 CDS is truncated, and there are 1 pathogenic variants in the truncated region.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 21-43774279-GGA-G is Pathogenic according to our data. Variant chr21-43774279-GGA-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 55960.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr21-43774279-GGA-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CSTB | NM_000100.4 | c.218_219del | p.Leu73ProfsTer3 | frameshift_variant | 3/3 | ENST00000291568.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CSTB | ENST00000291568.7 | c.218_219del | p.Leu73ProfsTer3 | frameshift_variant | 3/3 | 1 | NM_000100.4 | P1 | |
CSTB | ENST00000639959.1 | c.85_86del | p.Leu29ProfsTer3 | frameshift_variant | 2/2 | 5 | |||
CSTB | ENST00000640406.1 | c.*293_*294del | 3_prime_UTR_variant | 2/2 | 2 | ||||
CSTB | ENST00000675996.1 | n.643_644del | non_coding_transcript_exon_variant | 3/3 |
Frequencies
GnomAD3 genomes ? AF: 0.0000526 AC: 8AN: 152218Hom.: 0 Cov.: 33
GnomAD3 genomes
?
AF:
AC:
8
AN:
152218
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251470Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135922
GnomAD3 exomes
AF:
AC:
5
AN:
251470
Hom.:
AF XY:
AC XY:
2
AN XY:
135922
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000241 AC: 353AN: 1461870Hom.: 0 AF XY: 0.000239 AC XY: 174AN XY: 727234
GnomAD4 exome
AF:
AC:
353
AN:
1461870
Hom.:
AF XY:
AC XY:
174
AN XY:
727234
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000526 AC: 8AN: 152218Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74362
GnomAD4 genome
?
AF:
AC:
8
AN:
152218
Hom.:
Cov.:
33
AF XY:
AC XY:
4
AN XY:
74362
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Unverricht-Lundborg syndrome Pathogenic:5Other:1
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2005 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 30, 2022 | Variant summary: CSTB c.218_219delTC (p.Leu73ProfsX3) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2.5e-05 in 282872 control chromosomes (gnomAD). c.218_219delTC has been reported in the literature in individuals affected with Unverricht-Lundborg Syndrome (e.g. Lafreniere_1997, Lalioti_1997, Bespalova_1997). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating protein function, and found that the variant does not localize to the lysosomes which may contribute to misfunction (Alakurtti_2005). Five ClinVar submitters have assessed the variant since 2014: one classified the variant as likely pathogenic, and four as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Jan 27, 2016 | The c.218_219delTC (p.Leu73Profs*3) frameshift variant in the CSTB gene has been previously reported as heterozygous in three affected individuals with autosomal recessive Myoclonic epilepsy of Unverricht and Lundborg (Bespalova et al., 1997; Lafrenière et al., 1997; Lalioti et al., 1997). This frameshift variant is predicted to cause a protein termination in exon 3 (out of a total of 3 exons in the coding sequence). The C-terminal end of the protein, which is truncated by this variant, is important for normal protein function (Pol and Bjork, 1999). Nonsense mutations in the CSTB gene have been reported as pathogenic (Gln47*, Arg68*), and thus, loss of function is a known mechanism of disease. Additionally, in vitro functional studies have shown this variant leads to abnormal localization of the protein within the cell, similar to other pathogenic variants (Cipollini et al., 2008; Alakurtti et al., 2005). This c.218_219delTC has been reported at low frequency in the population databases (Exome Sequencing Project [ESP] = NA, 1000 Genomes = NA, and ExAC = 0.001%) and is predicted to be located in an evolutionarily conserved region (GERP = 5.46). Therefore, this collective evidence supports the classification of the c.218_219delTC (p.Leu73Profs*3) as a recessive Likely Pathogenic variant for Myoclonic epilepsy of Unverricht and Lundborg. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 23, 2021 | - - |
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 18, 2023 | Published functional studies suggest that the variant does not localize to lysosomes as compared to unaffected controls (Alakurtti et al., 2005; Cipollini et al., 2008); Frameshift variant predicted to result in protein truncation as the last 26 amino acids are replaced with 2 different amino acids, although loss-of-function variants have not been reported downstream of this position in the protein; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 9054946, 9342192, 7543407, 17003839, 30669344, 17920138, 15483648, 9012407) - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 31, 2023 | PP4, PM2, PS3, PS4_moderate, PVS1_strong - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Sep 16, 2021 | This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in at least one individual with clinical features associated with this gene. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 28, 2022 | The c.218_219delTC (p.L73Pfs*3) alteration, located in exon 3 (coding exon 3) of the CSTB gene, consists of a deletion of 2 nucleotides from position 218 to 219, causing a translational frameshift with a predicted alternate stop codon after 3 amino acids. This alteration occurs at the 3' terminus of the CSTB gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 26 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function. Based on data from gnomAD, this allele has an overall frequency of 0.003% (7/282872) total alleles studied. The highest observed frequency was 0.005% (6/129176) of European (non-Finnish) alleles. This mutation has been reported in three unrelated individuals with Unverricht-Lundborg disease (EPM1) (Bespalova, 1997; Lafrenière, 1997; Lalioti, 1997). A second mutation (expansion of the dodecamer repeat) was identified in one of the individuals. Studies of bovine CSTB have shown that some of the C-terminal residues affected by this truncation are important for protein function (Pol, 1999). In addition, this protein truncation is predicted to be structurally destabilizing and to disrupt binding of target proteins (Ambry internal data; Stubbs, 1990; Jenko Kokalj, 2007). Functional analysis demonstrated that levels of CSTB mRNA were significantly decreased in cells from patients heterozygous for the CSTB c.218_219delTC (p.L73Pfs*3) alteration compared to unaffected individuals (Lafrenière, 1997; Bespalova, 1997). When the L73Pfs*3 protein was expressed in vitro, the mutant protein had diffuse distribution in the cytoplasm and nucleus and did not colocalize with lysosomes (Alakurtti, 2005). Based on the available evidence, this alteration is classified as pathogenic. - |
Progressive myoclonic epilepsy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 21, 2023 | This sequence change creates a premature translational stop signal (p.Leu73Profs*3) in the CSTB gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 26 amino acid(s) of the CSTB protein. This variant is present in population databases (rs796943858, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with progressive myoclonus epilepsy type 1 (PMID: 9012407, 9054946, 9342192). This variant is also known as c.313_314del2, del2399TC, and 2404ΔTC. ClinVar contains an entry for this variant (Variation ID: 55960). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects CSTB function (PMID: 9342192, 15483648, 17920138). This variant disrupts the p.Leu73 amino acid residue in CSTB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10441148). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at